The application effect of percutaneous cryoablation for the stage IIIB/IV advanced non-small-cell lung cancer after the failure of chemoradiotherapy

被引:11
作者
Gao, Wei [1 ,2 ,3 ]
Guo, Zhi [1 ,2 ,3 ]
Shu, Shumiao [4 ]
Xing, Wenge [1 ,2 ,3 ]
Zhang, Weihao [1 ,2 ,3 ]
Yang, Xueling [1 ,2 ,3 ]
机构
[1] Tianjin Med Univ, Dept Intervent Therapy, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China
[2] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[4] Tianjin Univ Tradit Chinese Med, Dept Chinese Med, Tianjin, Peoples R China
基金
美国国家科学基金会;
关键词
Cryoablation; Lung cancer; Stage IIIB/IV; PALLIATIVE THORACIC RADIOTHERAPY; RADIOFREQUENCY ABLATION; FUNCTIONAL ASSESSMENT; RANDOMIZED-TRIAL; PHASE-III; CHEMOTHERAPY; THERAPY; MANAGEMENT; SAFETY;
D O I
10.1016/j.asjsur.2018.02.006
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background/Objective: A retrospective review is required to assess the application effect of percutaneous cryoablation on the stage IIIB/IV advanced non-small-cell lung cancer (NSCLC) after the failure of chemoradiotherapy. A total of twenty-two cases with stage IIIB/IV advanced NSCLC after failure of chemoradiotherapy were enrolled. Methods: Computed Tomography (CT) was used for the assessment of tumor response, and Functional Assessment of Cancer Therapy-General (FACT-G) was applied for the evaluation of quality of life. After the treatment of cryoablation, we performed a follow-up analysis. Results: The primary technique effectiveness of 100% was observed in the one month of follow-up. At three months, local tumor progression was shown in 4 of 31 lesions (13.6%). The one-year survival rate of 81.8% and progression-free rate of 27.8% were obtained. Six patients died 7, 9, 10, 12, 15 and 22 months after treatment, respectively. Decreased scores of total quality of life at one week after cryoablation (P = 0.006), but increased scores at one month after cryoablation (P = 0.024) were observed, compared with pre-cryoablation. Conclusion: Cryoablation contributes to the effective local tumor therapy for stage IIIB/IV advanced NSCLC after the failure of chemoradiotherapy. (C) 2018 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services by Elsevier B.V.
引用
收藏
页码:530 / 536
页数:7
相关论文
共 50 条
  • [31] VINORELBINE PLUS CISPLATINUM FOR THE TREATMENT OF STAGE-IIIB AND STAGE-IV NON-SMALL-CELL LUNG-CARCINOMA
    GEBBIA, V
    CARUSO, M
    VALENZA, R
    TESTA, A
    CANNATA, G
    VERDERAME, F
    CIPOLLA, C
    CURTO, G
    OLIVERI, D
    CHIARENZA, M
    LATTERI, MA
    DIGESU, G
    GEBBIA, N
    ANTICANCER RESEARCH, 1994, 14 (3B) : 1247 - 1249
  • [32] Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer
    Romero Roman, Alejandra
    Campo-Canaveral de la Cruz, Jose Luis
    Macia, Ivan
    Escobar Campuzano, Ignacio
    Figueroa Almanzar, Santiago
    Delgado Roel, Maria
    Galvez Munoz, Carlos
    Garcia Fontan, Eva M.
    Muguruza Trueba, Ignacio
    Romero Vielva, Laura
    Cano Garcia, Jose Ramon
    Martinez Tellez, Elisabeth
    Partida Gonzalez, Concepcion
    Jimenez Lopez, Marcelo Fernando
    Jimenez Maestre, Unai
    Mongil Poce, Roberto
    Sanchez Lorente, David
    Alvarez Kindelan, Antonio
    Provencio Pulla, Mariano
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2021, 60 (01) : 81 - 88
  • [33] Phase II study of taxol combined with ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer
    Zaniboni, A
    Ardizzoni, A
    De Marinis, F
    Portalone, L
    Boni, C
    Meriggi, F
    Cafferata, MA
    Ariganello, O
    Torri, V
    Neumaier, CE
    Rosso, R
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (01): : 84 - 88
  • [34] CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma
    Cheng, Jian Y.
    Kananathan, Ratnavelu
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (12) : 1799 - 1801
  • [35] The Role of Osimertinib in Treatment Naive Epidermal Growth Factor Receptor-Mutated Stage IIIB or IV Non-Small-Cell Lung Cancer Patients
    Uprety, Dipesh
    Bista, Amir
    Vallatharasu, Yazhini
    Arjyal, Lubina
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2018, 12
  • [36] 18F-FDG PET-CT: predicting recurrence in patients following percutaneous cryoablation treatment for stage I primary non-small-cell lung cancer
    LoGiurato, Brendan
    Matthews, Robert
    Safaie, Elham
    Moore, William
    Bilfinger, Thomas
    Relan, Nand
    Franceschi, Dinko
    NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (09) : 908 - 913
  • [37] Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer -: A phase II study
    Cao, MG
    Aramendía, JM
    Salgado, E
    Aristu, J
    Monje, RM
    Algarra, SM
    Ordoñez, JM
    Brugarolas, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (05): : 480 - 484
  • [38] Computed Tomography-Guided Cryoablation for Adrenal Metastasis Secondary to Non-small-cell Lung Cancer
    Cheng, Jie-Fei
    Xu, Wen
    Liu, Pei-Pei
    IRANIAN JOURNAL OF RADIOLOGY, 2021, 18 (02)
  • [39] Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study
    Monnet, Isabelle
    Audigier-Valette, Clarisse
    Girard, Nicolas
    Vergnenegre, Alain
    Molinier, Olivier
    Souquet, Pierre Jean
    Blanchon, Francois
    Bonnetain, Franck
    Taguieva-Pioger, Naila
    Lamour, Corinne
    Wislez, Marie
    LUNG CANCER, 2016, 98 : 84 - 90
  • [40] Stage IV non-small cell lung cancer.: Duration of chemotherapy for locally advanced non small cell lung cancers
    Vergnenegre, A.
    REVUE DES MALADIES RESPIRATOIRES, 2006, 23 (05) : S72 - S77